SRR5088928
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088904 | — | — | 0.957 |
| 2 | SRR5088860 | — | — | 0.953 |
| 3 | SRR5088905 | — | — | 0.951 |
| 4 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.942 |
| 5 | ERR2208937 | — | — | 0.932 |
| 6 | TCGA-55-7281-01A-11R-2039-07 | — | cohortA1 | 0.925 |
| 7 | c5e09ad2-1f0b-4ea3-9565-a1664f1bb468 | — | — | 0.922 |
| 8 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.921 |
| 9 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.920 |
| 10 | SRR5088910 | — | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |